NBT Bank N A NY Has $17.22 Million Stake in Johnson & Johnson $JNJ

NBT Bank N A NY decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,761 shares of the company’s stock after selling 2,209 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of NBT Bank N A NY’s investment portfolio, making the stock its 18th biggest position. NBT Bank N A NY’s holdings in Johnson & Johnson were worth $17,224,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Sanford C. Bernstein upped their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday. Finally, Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.41.

Johnson & Johnson Stock Up 0.7%

Shares of JNJ opened at $190.97 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $192.10. The stock has a market capitalization of $459.92 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 2.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a fifty day moving average of $178.01 and a 200-day moving average of $163.56.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the company earned $2.82 EPS. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.